性别肯定激素治疗与跨性别及性别多元成人炎症性肠病发作风险
这项回顾性多中心研究纳入85例启动性别肯定激素治疗(GAHT)的跨性别及性别多元炎症性肠病(IBD)成人,比较GAHT启动前后一年内IBD发作发生率。启动前一年42例(49%)发作,启动后一年32例(38%)发作,P=0.06;启动时IBD活动者及接受睾酮治疗者发作风险更高。
要点
- GAHT启动前后一年IBD发作率分别为49%与38%,差异未达统计学显著(P=0.06)。
- 启动GAHT时IBD活动者发作风险更高,校正OR为5.1(95%CI 1.7-15.2)。
- 接受睾酮者发作风险高于雌激素者(51% vs 26%),校正OR为3.1(95%CI 1.2-8.1)。
核心结论
- GAHT启动后一年整体IBD发作风险未见增加,但启动前IBD活动者及接受睾酮治疗者更易发生IBD发作。
研究设计与样本
- 回顾性研究,覆盖5个IBD中心,纳入85例启动GAHT的跨性别及性别多元IBD成人。
- 发作定义为需要使用类固醇、IBD相关急诊就诊或需要更换IBD药物。
- 采用单因素分析及校正年龄和IBD类型的多因素logistic回归评估与IBD发作相关的因素。
主要发现
- 85例中46例(54.1%)接受雌激素,39例(45.9%)接受睾酮。
- GAHT启动前一年42例(49%)发作,启动后一年32例(38%)发作,P=0.06。
- 发作发生率按年龄、IBD类型或IBD治疗类型均无统计学显著差异。
- 启动GAHT时IBD活动者更易发作:单因素分析58% vs 24%(P=0.003),多因素分析校正OR 5.1(95%CI 1.7-15.2)。
- 接受睾酮者启动后一年更易发作:睾酮51% vs 雌激素26%(P=0.02),校正OR 3.1(95%CI 1.2-8.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Little is known about the impact of gender-affirming hormone therapy (GAHT) on transgender and gender diverse adults with inflammatory bowel disease (IBD). The primary aim was to evaluate the incidence of IBD flare in the year before and after GAHT initiation. METHODS: A retrospective study across 5 IBD centers. Flare was defined as need for steroids, IBD-associated emergency department visit, or need for IBD medication change. Factors associated with IBD flare were assessed with univariate analysis and multivariable logistic regression controlling for age and IBD type. RESULTS: A total of 85 transgender and gender diverse adults with IBD who initiated GAHT were included in this study. Forty-six (54.1%) received estrogen and 39 (45.9%) received testosterone. In the year before GAHT, 42 (49%) flared compared with 32 (38%) in the year after, P = 0.06. There was no statistically significant difference in incidence of flare by age, IBD type, or IBD therapy type. Individuals with active IBD at GAHT initiation were more likely to flare in univariate (58% vs 24%, P = 0.003) and multivariable analyses (adjusted odds ratio 5.1, 95% confidence interval 1.7-15.2). In both univariate and multivariable analyses, individuals who received testosterone were more likely to flare in the year after starting GAHT, testosterone: 51% vs estrogen: 26%, P = 0.02 with an adjusted odds ratio 3.1 (95% confidence interval 1.2-8.1). DISCUSSION: Although there was no overall increased risk of flare in the year after GAHT start, those with active IBD before hormone start and those who received testosterone were more likely to experience an IBD flare.
引用
- Bennett A, Field J, Newman KL, et al. Gender-Affirming Hormone Therapy and Risk of Inflammatory Bowel Disease Flare in Transgender and Gender Diverse Adults. Am J Gastroenterol. 2025. PMID: 40377244. doi:10.14309/ajg.0000000000003543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。